Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape in Targeted Protein Degradation

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This source reports on advances in stimulus-responsive nanoparticle-based PROTACs (nano-PROTACs), which aim to overcome existing challenges like poor cell permeability and systemic off-target effects by enabling controlled protein degradation through endogenous or exogenous stimuli, potentially enhancing therapeutic efficacy and reducing toxicity.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.